Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 0.66 |
| ▸ | PPARG | P37231 | 11/20 | 0.58 |
| ▸ | PPARD | Q03181 | 13/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074678 | 1.00 | PPARA (0.66) | PPARAPPARGPPARD | |
| SCHEMBL4082095 | 1.00 | PPARA (0.66) | PPARAPPARGPPARD | |
| SCHEMBL1706161 | 0.89 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL5407837 | 0.87 | PPARA (0.63) | PPARAPPARGPPARD | |
| SCHEMBL5391356 | 0.87 | PPARA (0.73) | PPARAPPARGPPARD | |
| SCHEMBL5391355 | 0.87 | PPARA (0.73) | PPARAPPARGPPARD | |
| SCHEMBL1856323 | 0.85 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL13649255 | 0.85 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL4075927 | 0.85 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL17680422 | 0.85 | PPARA (0.68) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | claimed |
| EP-2355810-B1 | COMPOUND FOR THE TREATMENT OF PSORIASIS | NOGRA PHARMA LTD (IE) | 2017-07-12 | — | — | EP | claimed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| EP-2811993-A2 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2014-12-17 | — | — | EP | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| EP-2355810-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| CN-101969943-A | Compounds for the selective treatment of the intestinal immunoinflammatory component of celiac disease | GIULIANI INT LTD | 2011-02-09 | — | — | CN | claimed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | claimed |
| WO-2010063470-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | PPARA 1519/4885PPARG 838/4885PPARD 938/4885 |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | PPARA 4/4885PPARG 3/4885PPARD 6/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | PPARA 4/4885PPARG 3/4885PPARD 6/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | PPARA 4/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.